ESMO Advanced Course on Lung Cancer in Immunotherapy
- Start date
- 03 Jul 2019
- End date
- 04 Jul 2019
- Location
- Zurich, Switzerland
Learning objectives
- Understanding the key players in tumour immunology
- Getting up-to-date on the role of immunotherapy in advanced NSCLC
- The role of biomarkers in selecting NSCLC patients for IT
- Mechanism of combining angiogenesis inhibition with checkpoint inhibition
- Management of IT toxicity and use of IT in specific subgroups of patients
Accreditation
The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Co-Chairs
- John B. Haanen, Netherlands
- Aurélien Marabelle, France